Japan · Delayed Price · Currency is JPY Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 112.67 billion. The enterprise value is 149.32 billion.
| Market Cap | 112.67B |
| Enterprise Value | 149.32B |
Important Dates
The next estimated earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 91.38 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Current Share Class | 91.38M |
| Shares Outstanding | 91.38M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | -13.16% |
| Owned by Insiders (%) | 9.20% |
| Owned by Institutions (%) | 28.01% |
| Float | 75.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 24.25 |
| PS Ratio | 3.37 |
| PB Ratio | 1.74 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 418.83 |
| P/OCF Ratio | 128.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 165.55, with an EV/FCF ratio of 555.11.
| EV / Earnings | n/a |
| EV / Sales | 4.47 |
| EV / EBITDA | 165.55 |
| EV / EBIT | n/a |
| EV / FCF | 555.11 |
Financial Position
The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.84.
| Current Ratio | 2.66 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | 72.16 |
| Debt / FCF | 202.25 |
| Interest Coverage | -33.01 |
Financial Efficiency
Return on equity (ROE) is -11.94% and return on invested capital (ROIC) is -3.47%.
| Return on Equity (ROE) | -11.94% |
| Return on Assets (ROA) | -1.64% |
| Return on Invested Capital (ROIC) | -3.47% |
| Return on Capital Employed (ROCE) | -3.10% |
| Weighted Average Cost of Capital (WACC) | 3.84% |
| Revenue Per Employee | 103.82M |
| Profits Per Employee | -24.23M |
| Employee Count | 322 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.85 |
Taxes
| Income Tax | -2.03B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.81% in the last 52 weeks. The beta is 0.25, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +21.81% |
| 50-Day Moving Average | 1,026.36 |
| 200-Day Moving Average | 956.00 |
| Relative Strength Index (RSI) | 59.33 |
| Average Volume (20 Days) | 1,236,355 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 33.43 billion and -7.80 billion in losses. Loss per share was -86.12.
| Revenue | 33.43B |
| Gross Profit | 25.43B |
| Operating Income | -3.63B |
| Pretax Income | -9.83B |
| Net Income | -7.80B |
| EBITDA | 754.00M |
| EBIT | -3.63B |
| Loss Per Share | -86.12 |
Balance Sheet
The company has 17.75 billion in cash and 54.41 billion in debt, with a net cash position of -36.66 billion or -401.18 per share.
| Cash & Cash Equivalents | 17.75B |
| Total Debt | 54.41B |
| Net Cash | -36.66B |
| Net Cash Per Share | -401.18 |
| Equity (Book Value) | 64.80B |
| Book Value Per Share | 709.19 |
| Working Capital | 25.07B |
Cash Flow
In the last 12 months, operating cash flow was 874.00 million and capital expenditures -605.00 million, giving a free cash flow of 269.00 million.
| Operating Cash Flow | 874.00M |
| Capital Expenditures | -605.00M |
| Depreciation & Amortization | 4.39B |
| Net Borrowing | -14.36B |
| Free Cash Flow | 269.00M |
| FCF Per Share | 2.94 |
Margins
Gross margin is 76.05%, with operating and profit margins of -10.86% and -23.34%.
| Gross Margin | 76.05% |
| Operating Margin | -10.86% |
| Pretax Margin | -29.40% |
| Profit Margin | -23.34% |
| EBITDA Margin | 2.26% |
| EBIT Margin | -10.86% |
| FCF Margin | 0.80% |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.69% |
| Shareholder Yield | -0.69% |
| Earnings Yield | -6.92% |
| FCF Yield | 0.24% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Nxera Pharma is 2,015.00, which is 68.76% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,015.00 |
| Price Target Difference | 68.76% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 21.21% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 0.99 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.99 |
| Piotroski F-Score | 5 |